Business

Know the Business — HUL

HUL is the toll-collector of Indian everyday consumption: a fully-distributed, supplier-financed, multi-category brand portfolio that reaches 9 of 10 Indian households and earns a 23% EBITDA margin and ~28% ROCE off a small invested-capital base. The live debate is whether mid-single-digit volume growth, plus mix-up, plus quick-commerce can deliver double-digit EPS growth at ~49× reported / ~52× underlying PAT. The market looks over-anchored on Q4 FY26's volume re-acceleration (USG 7%, UVG 6%) and under-weight on the structural drag from a saturated mass HPC base plus the March 2026 Middle East input shock.

1. How This Business Actually Works

HUL is a branded-FMCG flywheel running on negative working capital. It buys palm oil, crude-linked surfactants, agri inputs and packaging; converts them in 27 owned factories plus 50+ contract manufacturers into ~80 billion units a year; ships them out to ~3,500 distributors that fund ~9 million retail outlets; then defends share with ~9-10% of revenue in advertising. Distributors prepay (~19 debtor days). Suppliers wait (~154 payable days). Inventory turns in ~55 days. Net: the business runs on suppliers' cash — a ₹0 capital structure that lets a 23% operating margin compound at ~28% ROCE.

The incremental rupee of profit comes from three places, in order of importance: (a) mix-up within an existing category — a Lux user moving to Dove, a Wheel user to Surf Excel powder, a powder user to liquid; (b) new-format / market-making — Vim Liquid building dishwash from nothing into a >₹1,000 Cr franchise, Liquids in Home Care crossing ₹4,000 Cr; (c) channel premium — quick-commerce shoppers paying for convenience and skewing toward higher-tier SKUs. Volume in the legacy mass categories grows only mid-single digit. That trio is the entire growth thesis.

2. The Playing Field

HUL is the only listed Indian FMCG that runs the full HPC + Foods front simultaneously. Each of the six peers below is more focused, and most run higher returns inside their narrow franchise — but none has the same combination of scale, distribution depth and category breadth. The interesting read-across: scale buys you breadth, focus buys you margin and capital efficiency. The market pays Nestle and Britannia higher multiples per rupee of earnings precisely because their narrower foods franchise compounds faster on a smaller base.

The chart isolates the right question for an HUL investor. HUL sits in the low-ROCE, average-margin quadrant of pure FMCG peers — not because the business is worse, but because the GSK Consumer Healthcare merger in FY2020 added ~₹46,000 Cr of goodwill and equity, mechanically halving ROCE from north of 100% in FY2015-FY2020 to ~28% from FY2022 onward. Adjust capital employed for that goodwill and HUL's operating ROCE is closer to Nestle/Britannia territory. ITC's 37% ROCE is a red herring — it's a cigarette business with FMCG attached, not a comparable.

What good looks like, peer-by-peer:

• Nestle India sets the upper bound for what a premium, narrow, MNC-disciplined FMCG portfolio can earn (85% ROCE, 23% margin).
• Britannia sets the bound for a foods-only play with category dominance in biscuits (56% ROCE, 18% margin) — what HUL's Foods segment should aspire to, but currently runs at 18% EBIT margin too.
• Marico shows what a premium HPC pure-play with one dominant franchise (Parachute) can do at small scale.
• Dabur and Godrej CP are HUL's true category-by-category competitors and run materially lower ROCE — evidence that HUL is the structural leader in HPC, not the laggard.

3. Is This Business Cyclical?

Volumes are not cyclical; price, mix and gross margin are. Indians keep brushing teeth, washing clothes, drinking tea and bathing — kilos and grams of consumption hardly move. What moves is (a) the input-cost stack (palm oil, crude-linked surfactants, milk, FX), and (b) the willingness of consumers to trade up between price tiers. Both have a textbook 12-18 month cycle, and HUL absorbs both with a 1-2 quarter pricing lag.

The shape of the curve is the entire cycle thesis. Margin grinds higher in benign commodity periods (FY15-FY20), then plateaus or gives back 100-300 bps during input-cost shocks (FY21-FY23, and again FY27 setup). Pricing is always recovered eventually because HUL is the price-setter in most categories — but the gap between the cost shock and the recovery is when the multiple compresses. The Q4 FY26 transcript explicitly flagged a 2-5% price hike already taken in Fabric Wash and Household Care, signalling FY27 H1 will look like a recovery quarter, not a high-base quarter.

4. The Metrics That Actually Matter

Five numbers explain almost all of HUL's value creation and value loss. Anything else — revenue growth, headline PAT — is downstream of these.

The scorecard reveals the actual hierarchy: HUL leads on cash mechanics, ties with Nestle on margin, lags on capital efficiency only because of merger goodwill, and runs below the foods leaders on volume growth. Capital efficiency is misleading — strip out the GSK CH merger goodwill (a one-time IFRS adjustment) and HUL's operating ROCE is comfortably above 70%, in line with Nestle and Britannia.

5. What Is This Business Worth?

Value here is mostly determined by how much future earnings power can be wrung out of an already-saturated franchise, not by asset value, not by a stake-aggregation, and not by a normalized cycle bottom. The right lens is a single-engine compounder with two layers: a defensible core that grows with India's nominal GDP, and a portfolio of new-demand-space bets (premium beauty, lifestyle nutrition, quick-commerce-native SKUs) that must add 2-4 points of growth to justify the ~50× multiple.

SOTP is not the right lens. The four segments (Home Care 37%, Beauty & Wellbeing 21%, Personal Care 15%, Foods 25%) share the same distribution, same A&P engine, same supplier and working-capital structure, and same MNC parent. They cannot be sold or valued separately in any meaningful sense. The ice cream demerger is the only real SOTP event of the last decade, and it was an exception driven by structurally lower margins (~10% vs HUL ~24%) and a different cold-chain business model — it has now been separated.

HUL trades between the premium foods MNC anchor (Nestle India at 85×) and the mass/conglomerate floor (ITC at 19×) — closer to the premium end. The multiple is not unreasonable on a per-rupee-of-quality basis: HUL has the deepest distribution, the widest portfolio, and the lowest CCC in the set. But the multiple is only defensible if FY27-FY28 deliver 5-7% USG with EBITDA margin in the upper half of the 22.5-23.5% guidance band — anything below that compresses the multiple toward Dabur/Godrej levels (~45×). Below the price level, ask one question: is the mix-up + market-making + Q-commerce trio adding 200-300 bps of structural growth, or just rotating revenue? If the answer is structural, the stock is fairly priced. If it's rotation, it isn't.

6. What I'd Tell a Young Analyst

Three things matter, two are noise.

Matters most: track UVG and gross margin every single quarter. UVG is the only honest growth signal in this business — pricing growth without volume is a mix-degradation problem in disguise. Gross margin is the early warning on the next downcycle. When UVG decelerates below 3% and gross margin compresses simultaneously, HUL re-rates from ~50× to ~38-42× and stays there for 18-24 months. That has happened twice in the last decade.

Watch closely: the quality of the volume growth, not just the headline. Q4 FY26's 6% UVG is the highest in 12 quarters, but it is being delivered with a 2-5% price hike already loaded into the system for FY27 — meaning the underlying pull is softer than the print suggests, and a rebalancing between volume and price growth is mechanically built in. Also: bolt-on M&A ROIC. ₹3,500 Cr deployed across Minimalist, OZiva and the Palm undertaking is a real test of management's capital discipline, after a decade of near-100% payout.

The market is most likely getting wrong: the structural slowdown in mass HPC categories. Soap and detergent per-capita consumption in urban India is approaching maturity. The growth engine has already shifted to liquids, masstige beauty, lifestyle nutrition, and channel-of-the-future SKUs — but the consolidated revenue print obscures this because legacy categories still anchor 60%+ of sales. Read the segment commentary, not the headline.

Noise that gets too much airtime: (a) the parent-royalty drumbeat — the rate has been stable for years and any change would be telegraphed; (b) quarter-to-quarter palm-oil moves — the cycle is 12-18 months, and HUL has always recovered pricing; (c) the digital-first D2C threat — the most disruptive ones (Minimalist, OZiva) HUL has already bought, and the rest don't have the distribution to scale beyond metros.

The thesis question, sharpened: is HUL's premiumisation engine adding 2-3 points of structural growth on top of nominal-GDP-volume, or is it just rotating revenue between segments? If structural, 50× is fair. If rotation, the stock has nowhere to grow into.